VE
$30.35
-0.85
(-2.72%)
As of Oct 22, 2026, 12:14 PM EDT
Price history
Vera Therapeutics Inc Class a (VERA) is trading down at $30.35 (-2.72%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: May 14, 2021 · $11.00 offering · NASDAQ · View IPO details →
Vera Therapeutics Inc Class a net income history (FY2020–FY2025)
Net income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$52.2M | −$34.4M | −$90.9M | −$102.0M | −$167.2M | −$315.5M |
| Net income | −$53.4M | −$32.6M | −$89.1M | −$96.0M | −$152.1M | −$299.6M |
| EPS (diluted) | −$166.93 | −$2.43 | −$3.35 | −$2.25 | −$2.75 | −$4.66 |
| Balance sheet | ||||||
| Cash and equivalents | $53.7M | $79.7M | $43.5M | $45.7M | $92.6M | $354.7M |
| Total assets | $54.6M | $83.7M | $131.4M | $175.5M | $655.7M | $734.7M |
| Total liabilities | $4.33M | $14.2M | $54.5M | $73.9M | $78.5M | $130.2M |
| Long-term debt | $0 | $4.92M | $24.8M | $49.9M | $50.7M | $74.8M |
| Shareholders' equity | −$89.3M | $69.6M | $76.9M | $101.7M | $577.2M | $604.5M |
| Cash flow | ||||||
| Operating cash flow | −$34.8M | −$23.7M | −$67.6M | −$92.2M | −$134.7M | −$241.1M |
| Capital expenditure | $99.0K | $0 | $62.0K | $63.0K | $972.0K | $630.0K |
| Free cash flow | −$34.9M | −$23.7M | −$67.7M | −$92.2M | −$135.7M | −$241.7M |
| Share buybacks | — | — | — | $0 | $13.0K | $0 |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$49.8M | −$48.9M | −$57.2M | −$80.1M | −$83.9M | −$94.2M | −$125.1M | −$112.5M |
| Net income | −$46.6M | −$43.4M | −$51.7M | −$76.5M | −$80.3M | −$91.1M | −$121.0M | −$109.5M |
| EPS (diluted) | −$0.85 | −$0.72 | −$0.81 | −$1.20 | −$1.26 | −$1.39 | −$1.69 | −$1.52 |
| Balance sheet | ||||||||
| Cash and equivalents | $27.3M | $92.6M | $55.1M | $49.1M | $57.8M | $354.7M | $114.4M | $48.9M |
| Total assets | $368.6M | $655.7M | $610.2M | $578.5M | $517.5M | $734.7M | $621.7M | $533.0M |
| Total liabilities | $79.5M | $78.5M | $75.2M | $110.3M | $118.6M | $130.2M | $122.0M | $125.2M |
| Long-term debt | $50.5M | $50.7M | $50.9M | $74.5M | $74.6M | $74.8M | $75.0M | $75.2M |
| Shareholders' equity | $289.1M | $577.2M | $535.0M | $468.3M | $398.9M | $604.5M | $499.7M | $407.8M |
| Cash flow | ||||||||
| Operating cash flow | −$36.9M | −$39.2M | −$54.4M | −$54.8M | −$61.9M | −$70.0M | −$106.5M | −$100.3M |
| Capital expenditure | $238.0K | $645.0K | $187.0K | $208.0K | $133.0K | $102.0K | $23.0K | $0 |
| Free cash flow | −$37.1M | −$39.8M | −$54.6M | −$55.0M | −$62.0M | −$70.1M | −$106.5M | −$100.3M |
| Share buybacks | — | $0 | — | — | — | $0 | — | — |
From Vera Therapeutics Inc Class a's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Vera Therapeutics Inc Class a
- Headquarters
- Brisbane, California From SEC filings, Oct 2026
Recent News (3)
-
Nvidia Is Moving Deeper Into Intel, AMD Territory: Supermicro Rolls Out 256-CPU Vera Rack Nvidia Is Moving Deeper Into Intel, AMD Territory: Supermicro Rolls Out 256-CPU Vera Rack Yahoo Finance
-
Nvidia Is Moving Deeper Into Intel, AMD Territory: Supermicro Rolls Out 256-CPU Vera Rack Nvidia Is Moving Deeper Into Intel, AMD Territory: Supermicro Rolls Out 256-CPU Vera Rack Stocktwits
-
Nvidia announces plug and play Vera Rubin racks that can be shipped on a truck Nvidia says its DSX Pod AI Factory, which combines seven Vera Rubin racks in a shipping container, could cut the time to start serving AI tokens to 14 days.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International